Education
About Us
Working with TipRanks
Follow Us
bioAffinity Technologies, Inc. (BIAF)
NASDAQ:BIAF
RESEARCH TOOLSreports
BIAF Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.24 - $3.16
Previous CloseN/A
Volume17.91K
Average Volume (3M)19.54M
Market Cap
$12.78M
Enterprise Value$14.57M
Total Cash (Recent Filing)$83.11K
Total Debt (Recent Filing)$10.01M
Price to Earnings (P/E)―
Beta-2.61
Next Earnings
May 20, 2025EPS Estimate
-0.14Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.73
Shares Outstanding18,255,823
10 Day Avg. Volume57,826,474
30 Day Avg. Volume19,536,260
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)0.46
Price to Cash Flow (P/CF)-0.60
P/FCF Ratio0.00
Enterprise Value/Market Cap1.14
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit18.41
Enterprise Value/Ebitda-1.88
Forecast
1Y Price Target
$6.00Price Target Upside934.48% Upside
Rating ConsensusHold
Number of Analyst Covering1
---
bioAffinity Technologies, Inc. News
PremiumCompany Announcements
bioAffinity Technologies Reports Record Revenue for 2024
PremiumCompany Announcements
bioAffinity Technologies Adjusts CEO Compensation Package
PremiumCompany Announcements
bioAffinity Technologies Boosts Sales with CyPath Lung---
Bulls Say, Bears Say
Bulls Say
Commercialization StrategyEven without current FDA approval, BIAF’s commercialization strategy as an LDT is driving significant testing volume and revenue growth.
FDA ClassificationA potential FDA De Novo classification of CyPath, pending positive trial results, could broaden adoption and market reach.
Product AdoptionThe number of physician offices offering the CyPath Lung test increased significantly, indicating growing adoption of the diagnostic test.
Bears Say
Capital RequirementsThe company needs to raise additional capital immediately, which could lead to share dilution for current shareholders.
Revenue GuidanceThe company introduced 2025 revenue guidance significantly below prior estimates, leading to a downgrade of the stock to Hold.
---
Ownership Overview
28.25% Insiders
2.20% Mutual Funds
0.31% Other Institutional Investors
67.57% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
BIAF FAQ
What was bioAffinity Technologies, Inc.’s price range in the past 12 months?
bioAffinity Technologies, Inc. lowest stock price was $0.24 and its highest was $3.16 in the past 12 months.
What is bioAffinity Technologies, Inc.’s market cap?
bioAffinity Technologies, Inc.’s market cap is $12.78M.
When is bioAffinity Technologies, Inc.’s upcoming earnings report date?
bioAffinity Technologies, Inc.’s upcoming earnings report date is May 20, 2025 which is in 40 days.
How were bioAffinity Technologies, Inc.’s earnings last quarter?
bioAffinity Technologies, Inc. released its earnings results on Mar 31, 2025. The company reported -$0.19 earnings per share for the quarter, missing the consensus estimate of -$0.16 by -$0.03.
Is bioAffinity Technologies, Inc. overvalued?
According to Wall Street analysts bioAffinity Technologies, Inc.’s price is currently Undervalued.
Does bioAffinity Technologies, Inc. pay dividends?
bioAffinity Technologies, Inc. does not currently pay dividends.
What is bioAffinity Technologies, Inc.’s EPS estimate?
bioAffinity Technologies, Inc.’s EPS estimate is -0.14.
How many shares outstanding does bioAffinity Technologies, Inc. have?
bioAffinity Technologies, Inc. has 18,255,823 shares outstanding.
What happened to bioAffinity Technologies, Inc.’s price movement after its last earnings report?
bioAffinity Technologies, Inc. reported an EPS of -$0.19 in its last earnings report, missing expectations of -$0.16. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of bioAffinity Technologies, Inc.?
Currently, no hedge funds are holding shares in BIAF
---
Company Description
bioAffinity Technologies, Inc.
bioAffinity Technologies, Inc. (BIAF) is a biotechnology company focused on developing non-invasive diagnostics and cancer therapeutics. The company's core product is CyPath Lung, a diagnostic test designed to detect early-stage lung cancer. bioAffinity Technologies operates primarily in the healthcare and life sciences sectors, leveraging its expertise in cell biology and flow cytometry to improve disease detection and treatment.
---
BIAF Stock 12 Month Forecast
Average Price Target
$6.00
▲(934.48% Upside)
Technical Analysis
Best Analysts Covering BIAF
1 Year
1 Year Success Rate
0/3 ratings generated profit
1 Year Average Return
-85.00%
reiterated a buy rating 5 months ago
Copying Anthony Vendetti's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -85.00% per trade.
---